Atlas Trials

Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma

Clinical trial NCT04314843 · TERMINATED

Trial details

NCT number
NCT04314843
Sponsor
Kite, A Gilead Company
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed/Refractory Large B-cell Lymphoma
Start date
2020-05-26
Primary completion
2021-03-16
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.